Thomas Cahill serves as Executive at Prime Medicine, Inc., where they oversee executive responsibilities. Since joining the company, Thomas Cahill has executed 2 insider transactions totaling $6.8M, demonstrating a bullish approach to their equity position. Their most recent transaction on Oct 24, 2022 involved purchasing 400,000 shares valued at $6.8M.
Thomas Cahill currently holds 5,305,679 shares of Prime Medicine, Inc. (PRME), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Thomas Cahill has been a net buyer of PRME stock. They have purchased $6.8M and sold $0 worth of shares.
Thomas Cahill's most recent insider trade was on Oct 24, 2022, when they purchased 400,000 shares at $17.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |